

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H1 2019

<https://marketpublishers.com/r/S6C283AB61CEN.html>

Date: April 2019

Pages: 59

Price: US\$ 3,500.00 (Single User License)

ID: S6C283AB61CEN

Abstracts

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H1 2019

SUMMARY

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Steroid 17 Alpha Hydroxylase/17,20 Lyase - Pipeline Review, H1 2019, outlays comprehensive information on the Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) - Steroid 17-alpha-

hydroxylase/17, 20 lyase is an enzyme belonging to hydroxylase class that is encoded by CYP17A1 gene. It helps in conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. It catalyzes both the 17-alpha-hydroxylation and the 17, 20-lyase reaction. It is involved in sexual development during fetal life and at puberty. The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Hormonal Disorders which include indications Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Breast Cancer, Metastatic Breast Cancer, Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Prostate Cancer and Prostate Cancer.

Furthermore, this report also reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30)

The report reviews Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics and enlists all their major and minor projects

The report assesses Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or

Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) - Overview

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) - Companies Involved in

Therapeutics Development

DisperSol Technologies LLC

Johnson & Johnson

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) - Drug Profiles

abiraterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abiraterone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abiraterone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAE-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orteronel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seviteronel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CYP17 for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CYP17 Lyase for Breast Cancer and Castration Resistant Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) - Dormant Products

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) - Discontinued Products

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) - Product Development

Milestones

Featured News & Press Releases

Feb 05, 2019: Clinical Trial gives UK pathologist new hope

Oct 26, 2018: Court issues ruling in ZYTIGA patent infringement litigation

Oct 10, 2018: Janssen to present on ZYTIGA at ESMO 2018

Jun 06, 2018: NICE set to deny access to UK-discovered Zytiga (abiraterone acetate) with androgen deprivation therapy (ADT) for men with aggressive, early prostate cancer

May 16, 2018: Janssen to Present Data on ZYTIGA at ASCO 2018

Feb 15, 2018: Health Canada Approves New Indication for ZYTIGA (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer

Feb 08, 2018: ZYTIGA (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

Feb 08, 2018: ZYTIGA (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

Jan 25, 2018: Janssen to Present data on ZYTIGA at Prostate and Urothelial Cancers at ASCO GU 2018

Jan 18, 2018: Amerigen's petition leads to U.S. Zytiga patent invalidation

Jan 17, 2018: Argentum Pharmaceuticals Wins Patent Invalidation Trial against the Sole Remaining Patent Protecting Janssens ZYTIGA

Jan 17, 2018: Johnson & Johnson Issues Statement on ZYTIGA Inter Partes Reviews

Dec 05, 2017: Moffitt Cancer Center Uses Innovative Treatment Strategy to Overcome Drug Resistance

Nov 22, 2017: European Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancer

Nov 20, 2017: European Commission Extends License for Janssen's ZYTIGA Plus Prednisone / Prednisolone to Include Earlier Stage Prostate Cancer Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by DisperSol Technologies LLC, H1 2019

Pipeline by Johnson & Johnson, H1 2019

Dormant Projects, H1 2019

Discontinued Products, H1 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

COMPANIES MENTIONED

DisperSol Technologies LLC

Johnson & Johnson

I would like to order

Product name: Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H1 2019

Product link: <https://marketpublishers.com/r/S6C283AB61CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S6C283AB61CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970